Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation
Haesook T Kim1, Brent Logan2, Daniel J Weisdorf3
1Department of Data Science, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, Massachusetts.
Transplantation and Cellular Therapy
|May 18, 2021
Summary
Composite endpoints in allogeneic hematopoietic cell transplantation (alloHCT) simplify outcome evaluation but can complicate interpretation due to unequal component significance and opposing effects. Guidelines for their use are proposed.
Area of Science:
- Hematology
- Transplantation Biology
- Clinical Trial Design
Background:
- Composite endpoints are increasingly utilized in allogeneic hematopoietic cell transplantation (alloHCT) research.
- These endpoints combine multiple outcomes into a single measure for assessing intervention effectiveness.
Purpose of the Study:
- To critically evaluate the benefits and limitations of composite endpoints in alloHCT.
- To propose guidelines for the appropriate use and interpretation of these novel endpoints in clinical studies.
Main Methods:
- Review and analysis of recently published alloHCT studies employing composite endpoints.
- Assessment of the impact of component endpoint weighting and directionality on overall results.
Main Results:
- Composite endpoints offer a simplified summary of alloHCT outcomes.
- Potential for misinterpretation exists due to varying clinical significance and conflicting effects among component endpoints.
Conclusions:
- While valuable, composite endpoints in alloHCT require careful consideration of their components.
- Clear guidelines are needed to ensure accurate interpretation and application of these endpoints in research and clinical practice.
